Premium
Antiparkinsonian activity of single oral dose of PHNO
Author(s) -
Grandas F.,
Quinn N.,
Critchley P.,
Rohan A.,
Marsden C. D.,
Stahl S. M.
Publication year - 1987
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870020106
Subject(s) - agonist , medicine , pharmacology , parkinson's disease , adverse effect , anesthesia , disease , receptor
PHNO, a new D‐2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose‐ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.